140 related articles for article (PubMed ID: 12801741)
21. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
22. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
23. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
24. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
[TBL] [Abstract][Full Text] [Related]
25. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
[No Abstract] [Full Text] [Related]
26. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Jabbour E; Cortes J; Kantarjian H
Oncology (Williston Park); 2007 May; 21(6):653-62; discussion 663-4, 667-8. PubMed ID: 17564324
[TBL] [Abstract][Full Text] [Related]
27. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Hong FS; Mitchell CA; Zantomio D
Pathology; 2010 Jan; 42(1):84-5. PubMed ID: 20025487
[No Abstract] [Full Text] [Related]
28. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
Mariani S; Tornaghi L; Sassone M; Basciani S; Buzzetti R; Gambacorti-Passerini C; Spera G; Gnessi L
Leuk Res; 2010 Jan; 34(1):e5-7. PubMed ID: 19717189
[No Abstract] [Full Text] [Related]
29. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Narayanan KR; Bansal D; Walia R; Sachdeva N; Bhansali A; Varma N; Marwaha RK
Pediatr Blood Cancer; 2013 Jul; 60(7):1148-53. PubMed ID: 23322583
[TBL] [Abstract][Full Text] [Related]
30. G-CSF for imatinib-induced neutropenia.
Heim D; Ebnöther M; Meyer-Monard S; Tsakiris D; Linn M; Tichelli A; Gratwohl A
Leukemia; 2003 Apr; 17(4):805-7. PubMed ID: 12682643
[No Abstract] [Full Text] [Related]
31. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
Jönsson S; Standal T; Olsson B; Mellström D; Wadenvik H
Am J Hematol; 2012 May; 87(5):550-2. PubMed ID: 22407760
[TBL] [Abstract][Full Text] [Related]
32. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
Breccia M; Cannella L; Montefusco E; Frustaci A; Pacilli M; Alimena G
Leuk Res; 2008 Mar; 32(3):519-20. PubMed ID: 17804066
[No Abstract] [Full Text] [Related]
33. Multiple eruptive dermatofibromas related to imatinib treatment.
Llamas-Velasco M; Fraga J; Solano-López GE; Steegmann JL; García Diez A; Requena L
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):979-81. PubMed ID: 24321053
[No Abstract] [Full Text] [Related]
34. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
35. Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.
Jalaeikhoo H; Ahmadzadeh A; Toogeh G; Haybar H; Valizadeh A; Charoosaei R; Yadollahzadeh M; Keyhani M
Arch Iran Med; 2011 Nov; 14(6):378-80. PubMed ID: 22039840
[TBL] [Abstract][Full Text] [Related]
36. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Marin D; Marktel S; Szydlo R; Klein JP; Bua M; Foot N; Olavarria E; Shepherd P; Kanfer E; Goldman JM; Apperley JF
Lancet; 2003 Aug; 362(9384):617-9. PubMed ID: 12944062
[TBL] [Abstract][Full Text] [Related]
37. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
38. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia.
Breccia M; Latagliata R; Carmosino I; Mandelli F; Alimena G
Leukemia; 2004 Jan; 18(1):182. PubMed ID: 14574325
[No Abstract] [Full Text] [Related]
39. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
[TBL] [Abstract][Full Text] [Related]
40. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Marin D
Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
